SCHEMBL4060811

SCHEMBL4060811

Cc1cc(Cl)ccc1Oc1ccc(NC(=O)c2ccccc2)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 1/20 0.56
GRM7 Q14831 1/20 0.56
GRM4 Q14833 1/20 0.56
PNLIP P16233 1/20 0.54
KCNQ3 O43525 3/20 0.53
KCNQ2 O43526 3/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
GAA P10253 1/20 0.53
P4HTM Q9NXG6 2/20 0.50
KCNE1 P15382 2/20 0.49
KCNQ1 P51787 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
MAPT P10636 2/20 0.48
HTR2C P28335 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4067290 0.90 GRM8 (0.53) GRM8GRM7GRM4MEN1KMT2A
SCHEMBL4064115 0.90 GRM8 (0.52) GRM8GRM7GRM4KCNQ3KCNQ2
SCHEMBL4065169 0.89 RAB9A (0.57) GRM8GRM7GRM4MEN1KMT2A
SCHEMBL4063387 0.89 NPC1 (0.53) GRM8GRM7GRM4KCNQ3KCNQ2
SCHEMBL4069994 0.88 NPC1 (0.54) MEN1KMT2AGAANPC1RAB9A
SCHEMBL4062244 0.88 PNLIP (0.60) GRM8GRM7GRM4PNLIPMEN1
SCHEMBL4065181 0.87 GRM4 (0.57) GRM8GRM7GRM4PNLIPMEN1
SCHEMBL4058614 0.87 GRM8 (0.53) GRM8GRM7GRM4PNLIPHTR2C
SCHEMBL4062656 0.86 PNLIP (0.60) GRM8GRM7GRM4PNLIPKMT2A
SCHEMBL4240750 0.86 PNLIP (0.56) GRM8GRM7GRM4PNLIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028945-B9 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC (US) 2009-02-18 EP disclosed
EP-1028945-B1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC (US) 2007-07-11 EP disclosed
US-6458813-B1 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER AMGEN INC. 2002-10-01 US disclosed
US-20020035094-A1 Substituted pyridine compounds and methods of use AMGEN INC. 2002-03-21 US disclosed
US-6333341-B1 TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS AMGEN INC. 2001-12-25 US disclosed
US-6184237-B1 Substituted pyridine compounds and methods of use AMGEN INC. 2001-02-06 US disclosed
EP-1028945-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS Amgen Inc. (US) 2000-08-23 EP disclosed
US-6022884-A PROPHYLAXIS OR TREATMENT OF INFLAMMATION AMGEN INC. (US) 2000-02-08 US disclosed
WO-1999024404-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035094-A1 Substituted pyridine compounds and methods of use IL1B, IL6, IL1A GRM8 994/4885GRM7 2968/4885GRM4 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.